Immunome, Inc.

NASDAQ:IMNM

Biotechnology

Healthcare
$16.78 -2.26%

-$0.42 today

Market cap
$1.98B
Beta
2.07
P/E (TTM)
-9.1
EPS (TTM)
-$1.99
52W Low $7.96High $27.65

Volume 1.41M

Average 1.23M

IMNM Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Immunome, Inc.NASDAQ: IMNM

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 113.56M shares rose 29.1% year over year, behind the +34.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +93.1% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +29.1% toward the trailing-twelve-month pace of +34.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
113.56M+0.3% QoQ
Last fiscal yearDec 2025
87.35M+49.0% YoY
LTMSep 2026
106.83M+34.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+29.1%——
1 year+49.0%——
3-year CAGR+93.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
87.35M USD
Year-over-year change
+49.0%
4-year CAGR
+65.9%

Weighted Avg Shares vs competitors

How IMNM compares with its peers on the latest reported figures

  • IMNM's LTM Sep 2026 weighted avg shares of 106.83M shares is the 3rd highest of the 11 companies compared; the peer median is 66.32M shares.
  • Its year-over-year change of +34.8% is the 2nd highest of 11, against a peer median of +11.9%.
  • Over three fiscal years its annual growth of +93.1% compares with a peer median of +19.0%.
IMNM Competitors Peer median
Weighted Avg Shares for IMNM and competitors
Company Period LTM YoY 3-year CAGR
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
IMTXImmatics N.V.LTM Mar 2026125.95M +14.7%+22.1%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 202682.39M +23.5%+19.3%
CLDXCelldex Therapeutics, Inc.LTM Sep 202672.36M +9.0%+12.4%
BCYCBicycle Therapeutics plcLTM Mar 202669.4M +7.1%+32.7%
MGNXMacroGenics, Inc.LTM Mar 202663.24M +0.8%+0.9%
IMCRImmunocore Holdings plcLTM Mar 202650.45M +0.8%+3.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
IMMXImmix Biopharma, Inc.LTM Mar 202634.62M +19.9%+33.4%
STROSutro Biopharma, Inc.LTM Mar 20266.42M -22.0%+18.8%
Peer median (excluding IMNM) 66.32M+11.9%+19.0%

Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0014.02M9.04M6.94M
Cost of Revenue00002.96M
Gross Profit0014.02M9.04M3.99M
Gross Margin——100.0%100.0%57.4%
Research & Development14.11M23.27M23.09M129.54M174.33M
Selling, General & Admin11.09M13.63M19.66M32.96M43.77M
Operating Expenses25.2M36.9M123.55M314.84M218.1M
Depreciation & Amortization755K631K728K2.1M2.96M
EBITDA(23.95M)(36.26M)(28M)(151.35M)(209.44M)
EBITDA Margin——-199.7%-1674.1%-3017.4%
Operating Income(25.2M)(36.9M)(109.53M)(305.8M)(214.11M)
Operating Margin——-781.4%-3382.4%-3084.8%
Interest Income10K5K2.72M12.84M11.72M
Interest Expense10K5K000
Other Income / Expenses493K5K2.72M12.84M1.72M
Income Before Tax(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Pre-Tax Margin——-761.9%-3240.4%-3060.0%
Income Tax Expense00000
Net Income(24.71M)(36.9M)(106.81M)(292.96M)(212.39M)
Net Margin——-761.9%-3240.4%-3060.0%
EPS (Basic)(2.14)(3.09)(5.38)(5.00)(2.43)
EPS (Diluted)(2.14)(3.09)(5.38)(5.00)(2.43)
Weighted Avg Shares11.54M12.13M19.84M58.64M87.35M
Weighted Avg Shares (Diluted)11.54M12.13M19.84M58.64M87.35M

Immunome, Inc.

NASDAQ:IMNM

Intrinsic Alpha fair value

Locked

Current Price

$16.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.